Shots:

• The P-III SEQUOIA trial evaluating efficacy & safety of Brukinsa vs bendamustine + rituximab (B+R) in patients with treatment-naïve CLL or SLL whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p])
• The interim analysis of trial met its 1EPs @ median follow-up of 25.8 mos- demonstrates improvement in PFS as assessed by IRC. The therapy was well-tolerated & consistent with its known safety profile
• Brukinsa (zanubrutinib) is a BTK inhibitor- currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies. The company plans to consult with global regulatory authorities

Ref: BeiGene | Image: BeiGene